| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5284 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2758 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1656 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1328 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 739 | 2021 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 662 | 2021 |
| Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a … Y Li, X Wang, DM Blau, MT Caballero, DR Feikin, CJ Gill, SA Madhi, ... The Lancet 399 (10340), 2047-2064, 2022 | 595 | 2022 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 584 | 2021 |
| Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised … X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley, NJ Andrews, ... The Lancet 398 (10303), 856-869, 2021 | 489 | 2021 |
| SARS-CoV-2 variants and vaccines PR Krause, TR Fleming, IM Longini, R Peto, S Briand, DL Heymann, ... New England Journal of Medicine 385 (2), 179-186, 2021 | 386 | 2021 |
| Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial ID Milligan, MM Gibani, R Sewell, EA Clutterbuck, D Campbell, E Plested, ... Jama 315 (15), 1610-1623, 2016 | 375 | 2016 |
| Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization … N Gossger, MD Snape, LM Yu, A Finn, G Bona, S Esposito, N Principi, ... Jama 307 (6), 573-582, 2012 | 367 | 2012 |
| Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum W Dejnirattisai, RH Shaw, P Supasa, C Liu, ASV Stuart, AJ Pollard, X Liu, ... The Lancet 399 (10321), 234-236, 2022 | 364 | 2022 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 332 | 2021 |
| Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data RH Shaw, A Stuart, M Greenland, X Liu, JSN Van-Tam, MD Snape The Lancet 397 (10289), 2043-2046, 2021 | 324 | 2021 |
| Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles … J Findlow, R Borrow, MD Snape, T Dawson, A Holland, TM John, A Evans, ... Clinical infectious diseases 51 (10), 1127-1137, 2010 | 310 | 2010 |
| Respiratory syncytial virus vaccination during pregnancy and effects in infants SA Madhi, FP Polack, PA Piedra, FM Munoz, AA Trenholme, EAF Simões, ... New England Journal of Medicine 383 (5), 426-439, 2020 | 306 | 2020 |
| Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial RC Read, D Baxter, DR Chadwick, SN Faust, A Finn, SB Gordon, ... The Lancet 384 (9960), 2123-2131, 2014 | 304 | 2014 |
| Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial MD Snape, KP Perrett, KJ Ford, TM John, D Pace, LM Yu, JM Langley, ... Jama 299 (2), 173-184, 2008 | 275 | 2008 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 269 | 2021 |
Merryn VoyseySenior Statistician, University of OxfordVerified email at paediatrics.ox.ac.uk
